Aurobindo Pharma enters US dermatology market

Aurobindo Pharma Limited (NSE: AUROPHARMA), through its subsidiary Acrotech Biopharma, has launched ADQUEY in the US for mild-to-moderate atopic dermatitis. The launch also marks Acrotech’s entry into the US dermatology segment through a dedicated business unit. Key details • ADQUEY contains difamilast 1%, a non-steroidal topical PDE4 inhibitor. • It is approved for patients aged two years and above with mild-to-moderate atopic dermatitis. • The product was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech for US commercialisation. • The relevant treatment segment was estimated at around $1.3 billion through July 2026. My view This is more than a single product launch because Aurobindo is building a specialised dermatology presence in the US. The opportunity depends on how quickly ADQUEY gains physician adoption and whether the new commercial platform can support more dermatology products later. Building a dedicated speciality sales setup also brings additional costs, so scale will matter. What I’m watching next I will watch prescription traction for ADQUEY, further dermatology launches and whether management starts disclosing the contribution of this new business. Stance: Positive on the entry into a higher-value speciality segment, but commercial adoption will decide the real impact. Disclosure: I do not have any holding or position in the stock mentioned above.